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hypothalamus; neurohypophysis; supraoptic nucleus NOREPINEPHRINE (NE) HAS LONG been recognized as an important neurotransmitter in the supraoptic nucleus (SON). Dense innervation of the SON by noradrenergic fibers was reported using the Falck-Hillarp histofluorescence technique that included dense innervation of the dendritic zone in the ventral glial lamina, as well as axosomatic contacts with magnocellular neuronal perikarya (25, 39) . Retrograde tracing and chemical ablation studies identified the source of this innervation as the A1 catecholamine neurons in the ventrolateral medulla and demonstrated an excitatory action of this catecholamine pathway on vasopressin (VP) neurons (8, 34) .
The A1 catecholaminergic projection from the ventrolateral medulla activates VP neurons in SON during hypotension/ hypovolemia, and this response requires corelease of ATP (4, 9, 10, 40) . We reported that simultaneous exposure of explants of the hypothalamo-neurohypophyseal system (HNS) to ATP and phenylephrine (PE; to mimic activation of ␣ 1 -adrenergic receptors by norepinephrine) results in a synergistic stimulation of VP and oxytocin (OT) release from the neurohypophysis that is sustained for hours (23) . ATP activation of purinergic P 2x -R (ligand-gated ion channels) and P 2y -R (G proteincoupled receptors) is required for this synergistic and sustained response (14) , but the role of ␣ 1 -adrenergic receptors remains to be determined and is the focus of this work.
Three ␣ 1 -R subtypes have been identified: ␣ 1 A, B, and D (6). Evidence for the possible expression of all three subtypes in magnocellular VP and/or OT neurons exists: ␣ 1 A is expressed in glial cells in the SON (16) , as well as elsewhere in the nucleus; ␣ 1 B is prominently expressed in SON neurons (1); and mRNA for ␣ 1 D is present in paraventricular nucleus (33) . In heterologous expression systems, these subtypes differ in their cellular localization (5), in their rate of ligand-induced internalization (5) , and in the genes they induce (15) . Although it is not known whether they behave similarly in neurons, the possibility that the conversion of the transient response to PE to a sustained response in the presence of ATP reflects either a shift in ␣ 1 -R subtype expression or the recruitment of additional subtypes is an intriguing hypothesis. Therefore, we used ␣ 1 -R subtype-selective antagonists to evaluate the contribution of each ␣ 1 -R subtype to the Ca 2ϩ responses to PE alone and in combination with ATP, and to the synergistic stimulation of VP/OT release induced by ATPϩPE. The current studies provide evidence that multiple subtypes of ␣ 1 -Rs contribute to the sustained elevation in VP/OT release induced by exposure to ATPϩPE. Since we showed previously that both P 2x and P 2y purinergic receptors are required for the response to ATPϩPE (14) and now show that continued activation of ␣ 1 -Rs is required, these findings suggest that corelease of ATP and NE by the A1 pathway allows for sustained stimulation of VP and OT release during hypovolemia and hypotension. During hemorrhage or sepsis, sustained release of VP is essential to prevent cardiovascular collapse leading to hemorrhagic or septic shock (28, 30, 37) .
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats [CRL:CD(SD)Br; Charles River Laboratories, Wilmington, MA] were used. All protocols used were performed in accordance with the National Institutes of Health's Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Colorado, Denver.
Hypothalamo-Neurohypophyseal Explant Preparation
Explants of the HNS were used for calcium imaging and hormone release studies. Explants were prepared as described previously from male rats [125-150 g; (42) ]. HNS explants include the SON neurons, their axons, and axon terminals in the neural lobe, as well as the organum vasculosum of the lamina terminalis and suprachiasmatic and arcuate nuclei. They do not include the paraventricular nucleus.
Hormone Release from HNS Explants
Explants were positioned individually in perifusion chambers having a 500-l volume and perifused with modified F12 nutrient mixture at 2 ml/h, as described previously (42) . Perifusion medium is gassed (95% O 2-5% CO2) and warmed (37°C) immediately before entering the perifusion chamber. Following a 4-h equilibration period to allow hormone release to stabilize at the basal level, explants were either maintained under control conditions or exposed to adrenergic and purinergic agents as appropriate for each experiment. Because of warming and gassing of the medium prior to entering the chamber housing the explant, there is approximately a 40-min delay between the drug's addition and its observed effect on hormone release. Effluent was collected individually at 20-min intervals using a refrigerated fraction collector maintained at 4°C. VP and OT concentration in the perifusate was determined by radioimmunoassay as described previously (43) . VP and OT release from HNS explants reflects changes in hormone release from nerve terminals in the neural lobe, because although VP and OT are released from dendrites in the SON and VP from the suprachiasmatic nucleus (11), the amount from the neural lobe far exceeds these other sources (17) .
Data analysis. Basal VP/OT release was determined during the hour immediately preceding exposure to drugs. Hormone release in response to experimental manipulations is expressed as a percentage of this initial basal release for each explant. Basal release for the explants included in these studies was 82.95 Ϯ 11.82 pg/ml for VP and 141.12 Ϯ 25.87 pg/ml for OT (means Ϯ SE). ANOVA with repeated measures followed by post hoc simple main effects analysis was performed on log-transformed data to evaluate changes in hormone release and to compare responses between groups.
Calcium imaging. HNS explants were loaded with the calciumsensitive dye, fura-2 AM, as described previously (42) . They were placed in a recording chamber with the ventral surface up, allowing easy visualization of SON neurons using the optic chiasm as an anatomical landmark (42) . Magnocellular SON neurons were identified by the size of the cell body (Ͼ25 m in diameter) and their location adjacent to the optic chiasm. Explants were perifused at a rate of 3 ml/min with gassed (95% O 2-5% CO2) F12 nutrient mixture fortified with 1 mg/ml glucose and 1.7 mM CaCl2, and fura-2-loaded magnocellular neurons were alternately excited with 340 nm and 380 nm UV light from a xenon source (Sutter Instruments, Novato, CA). The 380-nm exposure time was between 200 and 500 ms and was tripled for the 340-nm exposure. Emitted light was passed through a 60ϫ fluor water immersion lens attached to an Olympus upright microscope and collected at 510 nm by an intensified charge-coupled device camera (Hamamatsu, Japan). Paired 340-and 380-nm images were acquired every 3 s using Slide-Book software (Intelligent Imaging, Denver, CO) for a period of 100 frames. The 340:380 ratio (R) was used as an index of the change in [Ca 2ϩ ]i. Rmax was determined in ionomycin-treated explants and far exceeded the highest R obtained with agents studied in these experiments (42) . R data are presented as a percentage of the basal 340:380 R for each cell determined from the 10 frames preceding drug exposure. Explants were allowed to equilibrate for 1 h. Mean Ϯ SE of the percentage values from individual neurons were calculated and plotted. Parametric one-way ANOVA (F value) followed by Student-Newman-Keuls individual mean analysis or Kruskal-Wallis one-way ANOVA on ranks (H value) followed with Dunn's individual mean analysis was used to determine significant group differences in the peak and sustained responses.
Pharmacological agents. ␣ 1-R agonists and antagonists used to characterize the role of ␣ 1-Rs and specific subtypes included: phenylephrine (PE, 100 M), a broad spectrum ␣ 1-R agonist (27) ; benoxathian (Benox, 10 M), a broad-spectrum ␣ 1-R antagonist (26); WB4101 (100 nM) and 5-methylurapidil (5MU, 1 M), ␣ 1A-R selective antagonists (18, 29) ; AH11110 (100 nM), a selective ␣ 1B-R antagonist (13); and BMY7378 (10 or 100 nM), a selective ␣ 1D-R Fig. 1 . Effect of benoxathian (Benox; 10 M), an ␣1-R antagonist, on vasopressin (VP; A, C) and oxytocin (OT; B, D) release from hypothalamo-neurohypophyseal system (HNS) explants. Explants were allowed to equilibrate for 4 h. Basal hormone release was determined for each explant at the end of this period, and subsequent hormone release was expressed as a percentage of that basal level. Explants were subsequently maintained under basal conditions (control) or exposed to ATPϩ phenylephrine (PE) (100 M each) during the period shown by the red bar. Data for the control group were combined from explants run simultaneously with the early addition and late addition groups. Exposure to ATPϩPE without benoxathian (ATPϩPE) significantly increased VP and OT release compared with control. Benoxathian was present in the medium perifusing the explant during the period indicated by the green bar (Benox:ATPϩPE or ATPϩPE: Benox). The addition of benoxathian 1 h prior to ATPϩPE (A and B) did not alter basal VP (A) or OT release (B), but eliminated the ATPϩPE-induced increase in VP (F ϭ 1.228, P ϭ 0.2936) and OT release (F ϭ 0.04). The addition of benoxathian 2 h after ATPϩPE attenuated but did not completely eliminate ATPϩPE stimulation of VP and OT release (C and D).
antagonist (31) . All agents were obtained from Sigma-Aldrich except BMY7378, which came from Tocris Bioscience. In the calcium imaging protocols, antagonists were added 1-2 min before PE. In hormone release studies, antagonists were added either 1 h before ATPϩPE (early addition protocol) or 2 h after ATPϩPE (late addition protocol) and required ϳ40 min to reach the explant.
RESULTS
Role of ␣ 1 -Rs in ATPϩPE Stimulation of VP/OT Release
Our original finding that combined exposure of HNS explants to ATPϩPE converted the small, transient increases in VP/OT release induced by either ATP or PE to larger and sustained responses implicated a role for ␣ 1 -Rs in the synergistic response to ATPϩPE (23), because PE is selective for ␣ 1 -Rs (27) . We now confirm that an ␣ 1 -R-selective antagonist, benoxathian [(21, 26) ; 10M], prevents ATPϩPE stimulation of VP and OT release from perifused HNS explants when added to the perifusate 1 h in advance of ATPϩPE (Fig. 1, A  and B) . VP release increased significantly during exposure to ATPϩPE compared with control explants (F ϭ 20.01; P ϭ 0.0021). Although benoxathian did not alter basal release prior to the addition of ATPϩPE, it prevented the ATPϩPE response (F vs ATPϩPE ϭ 12.38, P ϭ 0.0079; F vs CONT ϭ 1.228, P ϭ 0.2936). OT release was also stimulated by ATPϩPE compared with control (F ϭ 11.83, P ϭ 0.009), and this effect was prevented by the prior addition of benoxathian [F vs ATPϩPE ϭ 10.83, P ϭ 0.013; F vs CONT ϭ 0.04, not significant (NS); Fig. 1B ].
Since we have previously shown that sustained stimulation of VP and OT release by ATPϩPE requires recruitment of desensitization-resistant P 2x -Rs (14), we evaluated the possibility that once those receptors are recruited, continued ␣ 1 -R activation is not required to sustain VP and OT release. As shown in Fig. 1C , benoxathian reduced the sustained stimulation of VP release even when added 2 h after the response to ATPϩPE had been established. VP release was initially stimulated by ATPϩPE. The presence of benoxathian during hours 7.6 -9 of perifusion significantly reduced VP release, such that it was significantly less than observed with ATPϩPE (F vs ATPϩPE ϭ 6.588, P ϭ 0.0304), but it did remain above control (F vs CONT ϭ 11.16, P ϭ 0.0086). OT release was also diminished by the presence of benoxathian during hours 7.6 -9, but it was not significantly different from ATPϩPE (Fig. 1D) .
Similarly, as shown in Fig. 2 , A and B, removal of PE following 2 h of perifusion with ATPϩPE decreased both VP and OT release compared with explants that continued to be perifused with either ATPϩPE (VP, P ϭ 0.002; OT, P ϭ 0.017) or explants that continued to be perifused with PE in the absence of ATP (VP, P ϭ 0.001; OT, P ϭ 0.003). These observations support the interpretation that continued activation of ␣ 1 -Rs are required for the sustained response to ATPϩPE. In conjunction with our previous findings that P 2x 2/3 and P 2x 7-R antagonists attenuate sustained VP release (14) , these findings support the interpretation that continuous exposure to PE is required to maintain P 2x 2/3 and/or P 2x 7-R function. This could reflect the necessity to maintain the P 2x receptors in an activated state perhaps mediated by PKC phosphorylation. The ability of PE alone to sustain VP release in conjunction with the finding that P 2x -R antagonists prevent the response may reflect the ability of PE to stimulate endogenous ATP release from SON astrocytes as demonstrated by Gordon et al. (16) . Thus, a requirement for exogenous ATP is replaced with endogenous ATP once synergism has been induced. Removing PE more effectively truncated ATPϩPE stimulation of VP/OT release than adding benoxathian, suggesting that the antagonist did not completely block the effect of PE.
Characterization of ␣ 1 -Rs in SON
To further characterize the role of ␣ 1 -Rs in the synergistic response to ATPϩPE, we used live-cell calcium imaging to study the intracellular signaling cascades initiated by PE and to identify the ␣ 1 -R subtypes responsible. Because ␣ 1 -Rs are G q/11 -coupled receptors, they are expected to activate IP3, resulting in release of calcium from intracellular stores. In addition, PE has been shown to depolarize SON neurons in HNS explants (3), which might induce calcium influx through voltage-gated calcium channels (VGCC). Therefore, experiments were performed to analyze the effect of PE on [Ca 2ϩ ] i and to assess the contribution of stored calcium and calcium influx. As shown in Fig. 3A , PE increased [Ca 2ϩ ] i . The response was essentially eliminated following treatment with thapsigarin (TG; Fig. 3A) . Although the PE-induced increase in [Ca 2ϩ ] i decayed more rapidly when calcium was removed from the external medium (Fig. 3B) , this reflects decreased refilling of calcium stores via store-operated channels rather than calcium influx through VGCC (Fig. 3C) , because the peak response to PE was not significantly reduced in the presence of a cocktail of VGCC blockers (5 mM nifedipine and 500 nM -conotoxin MVIIC to block L, P, and Q type channels). Thus, the increase in [Ca 2ϩ ] i observed in response to PE primarily reflects calcium release from intracellular stores. Calcium influx due to PE-induced depolarization and subsequent activation of VGCCs was either too small or too localized to be detectable with Fura-2. As shown previously (42), TG and removal of external calcium both attenuated the ATPϩPE-induced increase in [Ca 2ϩ ] i demonstrating contributions from both stored calcium and calcium influx to that response. These results demonstrate that the PE-induced [Ca 2ϩ ] i increase is primarily mediated through ␣ 1 A-Rs.
PE-Induced Increase in [Ca
␣ 1 A-R Contributes to the Ca 2ϩ Response to ATPϩPE
ATPϩPE induces a sustained elevation in [Ca 2ϩ ] i that is larger than observed with either ATP or PE alone (42) . To evaluate the role of ␣ 1 A-Rs in this sustained response, fura-2 AM-loaded HNS explants were exposed to ATPϩPE in the presence and absence of the ␣ 1 A-R antagonists, WB4101 and 5MU. As shown in Fig. 5 , A-D, the peak increase in [Ca 2ϩ ] i was slightly decreased by both antagonists, while the sustained increase in [Ca 2ϩ ] i was reduced by more than 50% to a level consistent with that observed with ATP alone (42) .
Inhibition of ␣ 1 -R Subtypes Does not Disrupt the Synergistic and Sustained Stimulation of VP/OT Release by ATPϩPE
Since antagonists of the ␣ 1 A-R blocked the calcium response to PE and attenuated the sustained calcium response to ATPϩPE, we examined the ability of one of the same antagonists, WB4101, at the same concentration (100 nM), to alter VP/OT release induced by ATPϩPE. As shown in Fig. 6 , WB4101 did not prevent the synergistic hormone release response to ATPϩPE either when added in advance of ATPϩPE (Fig. 6, A and B) or when added during the sustained component of the response (Fig. 6, C and D) . The ATPϩPE-induced increase in VP release was comparable in the presence or absence of WB4101 added 1 h prior to the ATPϩPE (F ATPϩPE vs. WB:ATPϩPE ϭ 1.93, P ϭ 0.1946) and was significantly greater than basal release (F ATPϩPE vs. control ϭ 8.456, P ϭ 0.0271). The same was true for OT release. OT release was stimulated by ATPϩPE (F ATPϩPE vs. control ϭ 9.294, P ϭ 0.0226), and the effect of ATPϩPE was comparable in the presence or absence of WB4101 (F ϭ ATPϩPE vs. WB:ATPϩPE ϭ 0.116, P ϭ 0.768). Furthermore, in contrast to the effect of withdrawing PE (Fig. 2) , blocking the ␣ 1 A-Rs by adding WB4101 2 h after ATPϩPE had established synergistic stimulation of VP and OT release did not reverse the sustained stimulation of either VP (F ATPϩPE vs. ATPϩPE:WB ϭ 0.83, NS) Fig. 6 . Effect of an ␣1A-R antagonist, WB4101 (100 nM) on VP (A, C) and OT (B, D) release from HNS explants. Explants were maintained under basal conditions (control) or exposed to ATPϩPE (100 M each) during the period shown by the red bar. WB4101 was added either 1 h before ATPϩPE (early addition; A and B) or 2 h after ATPϩPE (late addition; C and D) and was present during the period indicated by the blue bar. WB4101 did not alter basal VP or OT release (A and B) . C and D: data from the ATPϩPE group is combined with data from the explants that were exposed to ATPϩPE for 2 h prior to the addition of WB4101 normalized to the time of ATPϩPE addition (zero). ATPϩPE induced an increase in VP and OT release compared with control (VP: F ϭ 23.81, P ϭ 0.027; OT: F ϭ 4.81, P ϭ 0.038). The VP and OT responses to ATPϩPE were comparable in the presence and absence of WB4101 with both early and late addition of WB4101. Fig. 7 . Effect of an ␣1B-R antagonist, AH11110 (100 nM), on VP (A, C) and OT (B, D) release from HNS explants. Explants were maintained under basal conditions (control) or exposed to ATPϩPE (100 M each) during the period shown by the red bar. AH11110 was added either 1 h before ATPϩPE (early addition; A and B) or 2 h after ATPϩPE (late addition, C and D), and was present during the period indicated by the blue bar. AH11110 did not alter basal VP or OT release (A and B) . The VP and OT responses to ATPϩPE were comparable in the presence and absence of AH11110 (early addition). VP and OT release remained elevated when AH11110 was added 2 h after ATPϩPE (C and D; VP: F ϭ 15.4, P ϭ 0.0057; OT: F ϭ 8.07, P ϭ 0.025).
or OT release (F ATPϩPE vs. ATPϩPE:WB ϭ 2.95, NS). 5MU, the other ␣ 1 A-R antagonist that prevented the PE-induced increase in [Ca 2ϩ ] i , stimulated VP release independent of PE. Therefore, its effects on the ATPϩPE-induced hormone release were not interpretable (data not shown). Since the ␣1A-R antagonist did not prevent the sustained stimulation of VP/OT release, we also examined the effects of the ␣ 1 B and ␣ 1 D antagonists. Neither AH11110 (100 nM, ␣ 1 B-R antagonist) nor BMY7378 (10 M, ␣ 1 D-R antagonist) prevented the sustained increase in VP/OT release induced by ATPϩPE (Figs. 7 and 8 ). To maintain ␣ 1 -R subtype selectivity of these agents, higher concentrations of AH11110 and BMY7378 were not tested for their effects on hormone release. Taken together with the results of PE removal (Fig. 2) and benoxathian (Fig. 1) , these data suggest that multiple ␣ 1 -R subtypes participate in sustaining hormone release in response to ATPϩPE.
DISCUSSION
As one of the originally recognized neurotransmitters, the role of NE in regulation of VP/OT neurons has been extensively investigated. The action of NE on SON neurons is complex due to opposing effects of ␣-and ␤-adrenergic receptors (7, 38) : NE activation of ␤-adrenergic receptors can inhibit SON neurons, but NE activation of ␣ 1 -Rs reliably excites SON neurons and stimulates VP release (3, 32) . Thus, we used the ␣ 1 -R selective agonist, PE, to study the response to corelease of ATP and NE by A1 innervation of SON.
Since ␣ 1 -Rs are G q/11 -coupled receptors, they are expected to activate phospholipase C (PLC) resulting in formation of inositol triphosphate (IP3) and release of calcium from intracellular stores. The current live-cell calcium-imaging studies confirmed that the PE-induced increase in [Ca 2ϩ ] i primarily reflects release of calcium from intracellular stores, because depletion of intracellular calcium with TG essentially eliminated the calcium rise induced by PE. Although calcium influx through voltage-gated calcium channels would also be expected as a result of PE-induced depolarization of SON neurons (3), this was not detectable in the current studies.
Involvement of ␣ 1 -Rs in modulating purinergic stimulation of VP/OT release was suggested by our original observation that PE dramatically augmented the effect of ATP on VP and OT release and converted it from a transient response to a response that is sustained for hours (23) . The current finding that this synergistic effect is blocked by the ␣ 1 -R antagonist, benoxathian, confirms that PE acts via ␣ 1 -Rs. Furthermore, the finding that after the synergistic response is established, it is eliminated by withdrawal of PE and is attenuated by the addition of benoxathian demonstrates that continued activation of ␣ 1 -Rs is required to sustain the response.
Although prior anatomical studies suggested that all three ␣ 1 -R subtypes are expressed in SON (1, 16, 33) , the current studies are the first to provide functional evidence for subtypespecific expression in SON. The ability of two distinct ␣ 1 Aantagonists, WB4101 and 5MU, to prevent the PE-induced increase in [Ca 2ϩ ] i provides evidence for functional expression of the ␣ 1 A-R subtype in SON neurons, and its prominence in mediating PE-induced calcium release. However, the current studies also demonstrate that no single ␣ 1 -R subtype is responsible for the ATPϩPE-induced synergistic increase in VP and OT release. Although benoxathian, a nonsubtype-selective ␣ 1 -R antagonist blocked ATPϩPE-induced VP/OT release, none of the ␣ 1 -subtype selective antagonists (WB4101, AH11110, and BMY) blocked the response. The most convincing evidence that multiple receptor subtypes can support the synergistic response to ATPϩPE is the fact that the same concentration of WB4101 that prevented the increase in [Ca 2ϩ ] i induced by PE did not prevent ATPϩPE-induced VP and OT release. Involvement of multiple subtypes is not unexpected, because their shared ability to signal through the G q/11 cascade suggests redundancy in at least some of their effects. However, the ␣ 1 -R subtypes also interact with additional and different protein partners with diverse effects on gene expression and receptor desensitization (5, 19) . Thus, the potential for both redundant and distinct actions of the subtypes exists. The latter is supported by the blockade of the PEinduced increase in [Ca 2ϩ ] i being limited to the ␣ 1 A-R subtype. The involvement of ␣ 1 B-and/or ␣ 1 D-Rs in the sustained hormone response to ATPϩPE supports the possibility that ATP alters the temporal response to PE by recruiting additional subtypes of ␣ 1 -Rs.
Further evidence that G q/11 receptors play diverse roles in inducing and sustaining the hormone response to ATPϩPE comes from comparing the effects of PE activation of ␣ 1 -Rs with the effects of ATP activation of purinergic G q/11 -coupled receptors (P 2y -Rs). Activation of P 2y 1-Rs, like ␣ 1 -Rs, induces TG-sensitive release of stored calcium (41) , but a temporal difference exists in the effect of P 2y 1-R and ␣ 1 -R activation on VP and OT release. PE alone induces a rapid, but transient increase in VP/OT release from HNS explants with the peak effect evident within 30 min and a return to baseline by 80 min (23) . In fact, in earlier studies with finer temporal resolution of the hormone response, PE stimulation of hormone release was evident in less than 1 min (3). In contrast, the peak increase in VP/OT release induced by a P 2y 1-R agonist, 2MeSADP, occurred 1 h after the addition of the drug, and hormone release remained elevated relative to control explants throughout 3 h of exposure to 2-MeSADP (41). The rapid increase in hormone release induced by PE is correlated with and probably reflects PE-induced depolarization of SON neurons in HNS explants (3) . PE-induced depolarization of SON neurons is the result of inactivation of the A-type K ϩ current (32) , and the potassium channel subtype, K v4.2 , a major contributor to A-type current (44) , is present in postsynaptic membrane of SON neurons (2) . PKC and ERK/MAPK-mediated phosphorylation of K v4.2 has been demonstrated and results in decreased current expression (35, 36) most likely as a result of K v4.2 internalization (24) . In contrast, a P 2y 1-R agonist induced only a small depolarization in SON neurons (20) that may not be sufficient to directly generate hormone release. Thus, we postulate that the rapid increase in hormone release induced by PE reflects PKCmediated phosphorylation of K v4.2 potassium channels resulting in depolarization of the membrane while activation of P 2y 1-Rs initiates slower cellular events perhaps requiring new gene transcription. Selective PKC phosphorylation of K v4.2 channels by ␣1-R, but not P2Y1-R could occur if the receptors activate different PKC isoforms or could reflect subcellular receptor compartmentalization with different potassium receptor subtypes (22) . The latter possibility is suggested by the reports that in hippocampal and sympathetic neurons, P 2y 1-Rmediated depolarization occurs as the result of inhibition of M-type current, which is mediated by K v7 rather than K v4 channels (12) . Induction of gene transcription is consistent with P 2y 1-R activation being required to maintain the sustained component of ATPϩPE-induced VP and OT release but not being essential for the initial increase in VP and OT release induced by ATPϩPE (14) . Since ␣ 1 -R activation is also required for sustaining the synergistic hormone response to ATPϩPE, it is likely that activation of both ␣ 1 -Rs and P 2y -Rs is required to induce the pattern of gene expression required to sustain extended hormone release.
Perspectives and Significance
The cardiovascular collapse that occurs in hemorrhagic and septic shock is associated with a failure to maintain adequate VP secretion and can be successfully treated with exogenous VP (28, 37) . This demonstrates the homeostatic importance of the mechanisms that normally participate in maintaining a high rate of VP secretion during sustained hypotension. These complex and redundant mechanisms include corelease of multiple neurotransmitters (ATP and norepinephrine) and the ability of these neurotransmitters to activate families of diverse receptors with overlapping but distinct cell signaling cascades. This complexity ensures homeostatic stability under most physiological circumstances, but pathological perturbations (e.g., sepsis) can render it inadequate perhaps by undermining redundancies at the neurotransmitter, receptor, or cell signaling level.
